A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors

NCT04151186 | Unknown DMC

• 1 other identifier: CART-TM4SF1/CART-EpCAM-CAN-01
• Study Type: interventional
• Target: 72
• Locations: 0 countries
• Sites: N/A

Brief Summary

• Transmembrane 4 L Six Family Member 1 (TM4SF1) and Epithelial cell adhesion molecule (EpCAM) are both highly expressed in many epithelial-derived solid tumors.
• The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 or EpCAM have been generated respectively in our good manufacturing practices (GMP) facility and their anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies.
• Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 or EpCAM positive tumors. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 and CART-EpCAM cells will be examined inpatients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or lung cancer. And 9 patients for each cancer will be evaluated.
• Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

Conditions

Advanced Solid Tumor; Neoplasms

Keywords

CAR-T cells; Immunologic Factors; TM4SF1;EpCAM

Outcome Measures

Primary Outcomes (1)

• Safety assessed by Incidence of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

  1. After CAR-T cell infusion,the investigators will observe the potential adverse events related to the CAR-T cells infusion such as high fever, kidney failure and so on. 2. Adverse events are coded according to MedDRA 22.0. List total number of AEs and SAEs; Number of subjects with different types of AEs and SAEs, case-times and incidence.AEs and SAEs are graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE version 5.0).

  2 years

Secondary Outcomes (2)

• CAR-T cell testing

  2 years

• Overall response rate (ORR)

  2 years

Study Arms (1)

TM4SF1 and EpCAM positive CAR-T cells for solid tumors

EXPERIMENTAL

The present study is proposed to study advanced malignant solid tumors in adults, and the three escalating doses, namely, 2.0\~2.5. 4.0\~5.0 and 8.0\~10.0 (×10 \^6/kg), will be given.

Biological: TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy

Interventions

TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy BIOLOGICAL

Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations. Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank. Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min.

TM4SF1 and EpCAM positive CAR-T cells for solid tumors

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged≥18 years old and ≤75 years old when signing the informed consent; regardless of gender;
• Body weight\>40kg;
• Pathologically confirmed as pancreatic cancer, colorectal cancer, gastric cancer or lung cancer;
• Recurrent/refractory solid tumors unresponsive to the current standard treatment;
• At least one measurable lesion according to the RECIST 1.1 criteria, that is, the long diameter of the non-lymph-node lesion≥10 mm, or the short diameter of the lymph node lesion ≥15 mm on CT or MRI cross-sectional imaging; the longest axis of the measurable lesion≥10 mm on CT scan (slice thickness≤5 mm in CT scan);
• Acceptable hemopoietic ability: absolute neutrophil count (ANC) \>1.5×10\^9/L, platelet count \>1.0×10\^11/L, hemoglobin (HGB) \>90g/L (no blood transfusion within two weeks), absolute lymphocyte count (ALC )\>500×10\^9/L;
• Acceptable liver and kidney functions: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN in subjects without liver metastases and ≤3.5 upper limit of normal (ULN) in those with liver metastases; bilirubin≤1.5 ULN (excluding hyperbilirubinemia or non-liver-derived hyperbilirubinemia); creatinine ≤1.5 ULN and creatinine clearance rate≥40 mL/min;
• prothrombin time (PT)/international normalized ratio (INR) \<1.5 ULN and partial thromboplastin time (PTT)/activated partial thromboplastin time (APTT) \<1.5 ULN;
• Positive for TM4SF1 or EpCAM expression (expression≥25%), with three classifications; (1) Recurrent or existing lesions at the primary site with tumor tissue samples collected within 1 year, which are positive for TM4SF1 or EpCAM by immunohistochemistry; (2) New metastatic lesions at the non-primary sites, which are positive for TM4SF1 or EpCAM by immunohistochemistry; (3) Remaining tumor lesions at the primary site with tumor tissue samples collected more than 1 year ago, and the lesions are positive for TM4SF1 or EpCAM by immunohistochemistry based on re-biopsy.
• Women of child-bearing age (15-49 years old) must be negative for pregnancy test at 7 days before initiation of the treatment.
• Eastern Cooperative Oncology Group (ECOG) scores≤2.
• Expected survival no less than 12 weeks.

You may not qualify if:

• History of any radiotherapy and chemotherapy within 4 weeks before a single blood collection;
• History of any anti-programmed cell death protein 1 (PD1) and anti-Programmed cell death 1 ligand 1 (PD-L1) treatments within 12 weeks before a single blood collection;
• History of organ transplantation;
• Pregnancy or lactation;
• Uncontrolled infectious diseases, such as baseline hepatitis B virus (HBV) DNA≥2000 IU/ml, positive for anti-human immunodeficiency virus （HIV） antibody and hepatitis C virus (HCV)-RNA;
• Other active infection with clinical significance;
• History of other active malignancies in the past 5 years, excluding basal or squamous skin carcinoma, superficial bladder cancer, and breast cancer in situ which have completely healed and require no follow-up treatment;
• Serious autoimmune diseases or immunodeficiency disease, including those with confirmed severe autoimmune diseases and requiring long-term use (over 2 months) of systemic immunosuppressants (steroids) or having immune-mediated symptomatic diseases, such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (eg., Wegener's granulomatosis);
• Allergic diathesis and allergic to immunotherapy or relevant drugs;
• Organ failure; Heart: Grade III and IV ; or with hypertension uncontrolled by the standard treatment, history of myocarditis or myocardial infarction within 1 year; Liver: Class C according to the Child-Turcottei-Pugh System (CTP); Kidneys: Kidney failure and uremic syndrome; Lungs: Serious symptoms of respiratory failure; Brain: Disturbance of consciousness;
• Active bleeding, and thrombotic diseases requiring treatment;
• Uncontrollable pleural and peritoneal effusion requiring clinical treatment or intervention;
• T-cell cancers, such as T-cell lymphoma;
• Current on systemic steroid or steroid inhalers;
• Any mental diseases, including dementia and changes in mental status that may influence the understanding about the informed consent and questionnaire;

Sponsors & Collaborators

• suhaichuan: lead
• Shanghai Biomed-union Biotechnology Co., Ltd.: collaborator

Related Publications (8)

• Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC. Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18.

  PMID: 26089370 BACKGROUND

• Gao C, Yao H, Liu H, Feng Y, Yang Z. TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer. BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.

  PMID: 30876464 BACKGROUND

• Peng XC, Zeng Z, Huang YN, Deng YC, Fu GH. Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer. Cancer Med. 2018 Jun;7(6):2592-2600. doi: 10.1002/cam4.1494. Epub 2018 Apr 17.

  PMID: 29665316 BACKGROUND

• Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, Liu Y, Huang J, Lv H, Luo C, Feng KC, Yang QM, Li XL, Han W. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018 May 7;7(7):e1440169. doi: 10.1080/2162402X.2018.1440169. eCollection 2018.

  PMID: 29900044 BACKGROUND

• Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986 Aug;46(8):3917-23.

  PMID: 3731064 RESULT

• Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7059-63. doi: 10.1073/pnas.83.18.7059.

  PMID: 3462743 RESULT

• Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol. 1990 Jun;8(6):1083-92. doi: 10.1200/JCO.1990.8.6.1083.

  PMID: 2161448 RESULT

• Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother. 1993;36(4):267-73. doi: 10.1007/BF01740909.

  PMID: 8382560 RESULT

MeSH Terms

Conditions

Neoplasms

Interventions

TM4SF1 protein, human

Study Officials

• Helong Zhang, professor

  IEC of Institution for National Drug Clinical Trials ,Tangdu Hospital

  STUDY CHAIR

Central Study Contacts

Haichuan Su, professor

CONTACT

18629190366; suhc@fmmu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: October 29, 2019
• First Posted: November 5, 2019
• Study Start: November 20, 2019
• Primary Completion: May 20, 2021
• Study Completion: November 20, 2021
• Last Updated: November 5, 2019

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share